Syngene International Limited’s Post

That's fantastic news, Evosep Biosystems! The collaboration with the Jesper Velgaard Olsen Group at Novo Nordisk Foundation Center for Protein Research sounds incredibly promising. Automation, especially in sample digestion and loading, using the Opentrons Labworks Inc. OT-2 robot, has immense potential for high-throughput proteomics. Handling up to 192 samples in just 6 hours with enhanced sensitivity and reproducibility is a game-changer for biomarker discovery, significantly reducing costs with less starting material. The added automation in phosphopeptide enrichment expands its application scope, particularly beneficial for large-scale studies in oncology, where unraveling cellular signaling and protein interactions is crucial for advancing cancer research. #Biotechnology #DrugDiscovery #MassSpectrometry #Proteomics #Oncology #Automation #Innovation #ResearchAdvancements

A very interesting one that you can't miss provided by the experts of the RNAscope technology: https://lnkd.in/eXaKaCKB Register and get to know it all on how RNAscope can help you with Visualizing and Analyzing Multiomic Spatial Patterns of Your Target within the Tissue Micro-Environment with RNAscope™ Professional Assay Services team of experts February 13, 2024 @ 7 am PST / 10 am EST / 4 pm CET Presenters - Xiomara A Perez, Ph.D. and Farhat Mustafa, MD Agenda: Learn how to use RNAscope technology to -Co-detect vector and codon-optimized transgene, evaluate AAV biodistribution, capsid optimization, and safety assessment. -Optimize viral and non-viral delivery systems. -Visualize antisense oligos (ASOs), siRNAs, and other target RNAs and markers for RNA therapeutics. -Characterize biomarkers, checkpoint markers, cytokine and chemokine expression, and CAR-T cells together with immune cells within the tumor microenvironment. -Evaluate biomarkers identified from discovery programs and study tissue expression profiles. -Overview of our feasibility options for complex and customized image analysis.

We believe that standardization and automation will support the transition into new application like precision medicine and drug discovery. In collaboration with the Jesper Velgaard Olsen Group at Novo Nordisk Foundation Center for Protein Research, University of Copenhagen we co-authored a manuscript on fully automated workflows for high-throughput proteomics. By automating sample digestion and Evotip loading with the Opentrons Labworks Inc. OT-2 robot, it dramatically increases throughput, handling up to 192 samples in just 6 hours. This efficiency is paired with high sensitivity and reproducibility, crucial for reliable biomarker discovery. Notably, the method requires less starting material, reducing costs substantially. The added automation of phosphopeptide enrichment further broadens its application scope, making it ideal for large-scale studies in cancer research and beyond, where understanding cellular signaling and protein interactions is vital. #proteomics #highthroughput #sampledigestion #clinicalanalysis #lcms

A very big screen for a very important message!   I’m honored to have presented at this year's MS-Øresund conference hosted at Lundbeck, where I was invited to share insights on ‘Enhancing Quality Control of LC-MS for Biopharma-Centered Analysis’.   In my talk, I emphasized the critical aspects of controlling analysis variability, implementing QC standards, and strategically choosing setup parameters for reflecting the variability. Additionally, I showcased the automated tool developed for QC standard evaluation at Alphalyse A/S, leveraging supervised machine learning.   As you can see in the image, we have achieved a coefficient of variation (CV) under 13% between assays, and under 7% within assays – across 220+ vastly different Host Cell Protein projects ranging from monoclonal antibody drugs to cell and gene therapy – for our quantitative LC-MS analysis. The automated tool will help maintain this in the future.   Automation and reproducibility in mass spectrometry analyses were the main themes of the conference, with many speakers echoing similar sentiments. 🔄 It's encouraging to witness the growing acceptance of mass spectrometry as a robust and reproducible high-throughput analytical method for biopharma analysis. 🌐   A heartfelt thank you to the organizers for this opportunity to present my research and learn from the insights of others. 🙏   #MSØresundConference #LCMS #QualityControl #Automation #Reproducibility #BiopharmaAnalysis #MachineLearning

CAR-T or CAR-iMac?   Well, it might be tough to decide between the two, especially after reading this paper!   CAR-macrophages have a unique ability to tackle solid tumors in patients, but as an autologous therapy, it's a challenge to manufacture enough functional CAR-macrophages at-scale from a single patient.   To address this, (Abdin et al.), have leveraged a scalable 3D-automated bioreactor technology to differentiate and modify iPSCs to generate functional and scalable CAR-iMac products.   Key Findings:   -Better activity: CAR-iMacs demonstrated increased phagocytosis against CD19+ leukemic cells and higher secretion of IL-6 and TNF-α in comparison to control iMacs without the CAR.   -Specificity: CAR-iMacs phagocytosis correlated directly with CD19 surface antigen expression levels.   -Scalability: Adapted the iMac differentiation protocol to an automated 3D bioreactor, while maintaining the functionality and phenotype of the genetically modified iMacs. The authors of this paper were able to successfully show that CAR-iMacs had increased excitement, recognition against CD19+ leukemic cells and showed that they can be grown at scale from iPSCs. This makes iPSCs a much more attractive candidate in the world of cell therapy. Kudos to the authors for their research and findings!  #celltherapyjournalclub

🚀 Exciting Breakthrough in Facioscapulohumeral Muscular Dystrophy Research 🧬 Early data from Avidity Biosciences, Inc. show that their novel RNA therapy, del-brax (AOC 1020), has potential functional benefits for FSHD patients! Currently, there are no approved therapies 💡 Key Highlights💡: 👩⚕️Safety & Tolerability: The phase 1/2 trial showed del-brax is safe and well-tolerated, with no serious adverse events. 🧑🔬Gene Expression: Del-brax targets the abnormal DUX4 gene, showing over 50% mean reduction in DUX4-regulated genes at a 2 mg/kg dose. 🧑🔬Functional Improvement: Early data suggest improved muscle strength and function trends—a promising sign for FSHD patients! Del-brax has received FDA orphan and fast-track designations, highlighting its potential impact. #FSHD #RNAtherapy #MedicalResearch #Hope #Innovation #MuscularDystrophy #AvidityBiosciences #GenTherapy #DMD

👉🏼 Dive into the world of Circular RNAs (circRNAs) in our latest Spotlight Article, “Running in Circles? A Faster Way to Analyze circular RNAs”. In this article we explore why circular RNA matters, its promise in therapeutics, and potential role in pathology. Learn how you can save time and simplify your circRNA analysis. https://lnkd.in/ggx7fmMT Stay ahead of the curve and join us in unraveling the mysteries of circRNAs! #CircularRNA #CircRNA

👉🏼 Dive into the world of Circular RNAs (circRNAs) in our latest Spotlight Article, “Running in Circles? A Faster Way to Analyze circular RNAs”. In this article we explore why circular RNA matters, its promise in therapeutics, and potential role in pathology. Learn how you can save time and simplify your circRNA analysis. https://lnkd.in/ggx7fmMT Stay ahead of the curve and join us in unraveling the mysteries of circRNAs! #CircularRNA #CircRNA

👉🏼 Dive into the world of Circular RNAs (circRNAs) in our latest Spotlight Article, “Running in Circles? A Faster Way to Analyze circular RNAs”. In this article we explore why circular RNA matters, its promise in therapeutics, and potential role in pathology. Learn how you can save time and simplify your circRNA analysis. https://lnkd.in/ggx7fmMT Stay ahead of the curve and join us in unraveling the mysteries of circRNAs! #CircularRNA #CircRNA

The solution for your luxury problem of having too much spatial data? Let us analyze it for you. See how in this webinar.